Clinical trial
Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy
NCT01617226 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy
- Lead sponsor
- University of Birmingham
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2012
- Completion date
- December 31, 2020
- Enrollment
- 260 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.